Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Braune, Stefan; Lang, M; Bergmann, A; NTC Study Group 
Titel:
Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort. 
Abstract:
Although Fingolimod is registered as a second-line drug in relapsing-remittend multiple sclerosis (RRMS) in Europe there are no clinical studies available comparing Fingolimod (FTY) and Natalizumab (N). This observational cohort-study used health data routinely collected in outpatient neurology practices throughout Germany completing a treatment period of 12 months included 237 patients starting on N and 190 patients on FTY because of failure of the first-line treatment. Mean relapse rate drasti...    »
 
Zeitschriftentitel:
J Neurol 
Jahr:
2013 
Band / Volume:
260 
Heft / Issue:
12 
Seitenangaben Beitrag:
2981-5 
Sprache:
eng 
Print-ISSN:
0340-5354 
TUM Einrichtung:
Neurologische Klinik und Poliklinik